Investment in ADC Biotechnology

    Completion Date: 09/2017
    Target: ADC Biotechnology
    Deal Value: Undisclosed
    Details: HMT LLP, led by partner Paul Read advised Maven
    Capital Partners on its investment in anti-cancer drugs
    manufacturer ADC Biotechnology
    Funding: Maven Capital Partners
    Financial Due Diligence: HMT

    hmtllp.com

    HMT-NEW-LOGO-August-2016-copie